The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse r...

Descripción completa

Detalles Bibliográficos
Autores principales: Freedman, Mark S, Wolinsky, Jerry S, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Miller, Aaron E, Thangavelu, Karthinathan, Benamor, Myriam, Truffinet, Philippe, O’Connor, Paul W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891690/
https://www.ncbi.nlm.nih.gov/pubmed/28304217
http://dx.doi.org/10.1177/1352458517695468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891690/
https://www.ncbi.nlm.nih.gov/pubmed/28304217
http://dx.doi.org/10.1177/1352458517695468

Ejemplares similares